-
Product Insights
NewNet Present Value Model: Freeline Therapeutics Holdings Plc’s FLT-201
Empower your strategies with our Net Present Value Model: Freeline Therapeutics Holdings Plc's FLT-201 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FLT-201 in Gaucher Disease Type I
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FLT-201 in Gaucher Disease Type I report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FLT-201 in Gaucher Disease Type I Drug Details: FLT-201...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vargatef in Interstitial Lung Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vargatef in Interstitial Lung Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vargatef in Interstitial Lung Fibrosis Drug Details: Nintedanib (Vargatef) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – T-1301 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - T-1301 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. T-1301 in Solid Tumor Drug Details: T-1301 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevuparin Sodium in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevuparin Sodium in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sevuparin Sodium in Malaria Drug Details:Sevuparin sodium (DF-02) is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – T-1301
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry T-1301 Drug Details T-1301 is under development for the treatment of acute myeloid leukemia...
-
Product Insights
Net Present Value Model: Verbrinacogene setparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Verbrinacogene setparvovec Drug Details FLT-180a is...
-
Product Insights
Net Present Value Model: FLT190
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model FLT190 Drug Details FLT-190 is under...
-
Product Insights
Net Present Value Model: Rydapt
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Rydapt Drug Details Midostaurin (Rydapt, Mitikayd)...